Biofrontera (Biofrontera) Interest Expense : $-1.93 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Biofrontera Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biofrontera's interest expense for the three months ended in Mar. 2024 was $ -1.42 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.93 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biofrontera's Operating Income for the three months ended in Mar. 2024 was $ -5.47 Mil. Biofrontera's Interest Expense for the three months ended in Mar. 2024 was $ -1.42 Mil. Biofrontera did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biofrontera Interest Expense Historical Data

The historical data trend for Biofrontera's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera Interest Expense Chart

Biofrontera Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

-2.16

-2.90

-0.36

-0.37

-0.60

Biofrontera Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial												-0.09	-0.12	-0.16	-0.23	-1.42

Biofrontera Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.93 Mil.

Biofrontera (NAS:BFRI) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biofrontera's Interest Expense for the three months ended in Mar. 2024 was $-1.42 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-5.47 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $0.62 Mil.

Biofrontera's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Biofrontera did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Biofrontera (Biofrontera) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera Inc (NAS:BFRI) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

120 Presidential Way, Suite 330, Woburn, MA, USA, 01801

Website

https://www.biofrontera-us.com

Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. Its licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. its licensed product is Ameluz, which is a prescription drug approved for use in combination with the RhodoLED lamp series, for PDT (when used together, Ameluz PDT). including the complementary product BF-RhodoLED, and Xepi.

Executives

Heikki Lanckriet	director	C/O BIOFRONTERA INC., 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Eugene Frederick Leffler	officer: Chief Financial Officer	84 BAY DRIVE, SUDBURY MA 01776
Kevin Daniel Weber	director	119 BUCHANAN COURT, CELINA TX 75009
Borer John J Iii	director	1270 AVENUE OF THE AMERICAS, 16TH FLOOR, NEW YORK NY 10020
Beth J. Hoffman	director	5895 BLAZING STAR LANE, SAN DIEGO CA 92130
Loretta M. Wedge	director	21260 WACISSA DRIVE, VENICE FL 34293
Ag Biofrontera	10 percent owner	HEMMELRATHER WEG 201, LEVERKUSEN 2M D-51377
Erica F. Gates	officer: Controller	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Erica L. Monaco	director, officer: Chief Financial Officer/COO	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801
Hermann Luebbert	director, officer: Chief Executive Officer	C/O BIOFONTERA INC.,, 120 PRESIDENTIAL WAY, SUITE 330, WOBURN MA 01801